Skip to main content
    A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.45
    -0.03 (-5.40%)

    Market Cap: $131.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Akebia Ther (AKBA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Akebia Ther (AKBA) to earn -$0.16 per share in the fiscal year ending Dec 31, 2026, on revenue of $171.42M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.

    RatingAnalystsShare
    Strong Buy116.7%
    Buy466.7%
    Hold116.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 39.0%.

    Fiscal year ending Dec 31, 2026
    -$0.16
    EPS consensus, revenue $171.42M
    Fiscal year ending Dec 31, 2027
    -$0.33
    EPS consensus, revenue $104.56M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.16-$0.16 to -$0.161$171.42M$166.50M to $175.10M5
    Dec 31, 2027-$0.33-$0.33 to -$0.331$104.56M$75.30M to $140.81M6

    Quarterly Estimates

    The EPS consensus falls from -$0.04 for the quarter ending Dec 31, 2026 to -$0.09 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.04-$0.07 to -$0.018$32.80M$26.26M to $37.80M8
    Mar 31, 2027-$0.09-$0.09 to -$0.091$25.07M$18.60M to $30.50M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.11.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.16-$0.16-$0.16-$0.16-$0.11N/A
    Fiscal year ending Dec 31, 2027-$0.33-$0.36-$0.36-$0.36-$0.20N/A
    Quarter ending Mar 31, 2027-$0.09-$0.10-$0.10-$0.10-$0.06N/A

    Frequently Asked Questions About AKBA

    What is the AKBA stock forecast?

    Consensus analyst estimates put Akebia Ther's EPS at -$0.16 for the fiscal year ending Dec 31, 2026, on revenue of $171.42M. The consensus rating from 6 analysts is Buy.

    How do analysts rate AKBA stock?

    Of 6 analysts covering Akebia Ther, 1 rates it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from AKBA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.16, with estimates from -$0.16 to -$0.16 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.33, with estimates from -$0.33 to -$0.33 from 1 analyst.

    What revenue do analysts expect from Akebia Ther next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $171.42M, with estimates from $166.50M to $175.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $104.56M, with estimates from $75.30M to $140.81M.

    How many analysts cover AKBA?

    6 analysts rate Akebia Ther stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.